These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 17224758)

  • 21. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
    Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
    Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients.
    Chiselită D;
    Oftalmologia; 2007; 51(2):81-6. PubMed ID: 17937041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.
    Varma R; Hwang LJ; Grunden JW; Bean GW
    Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure.
    Toris CB; Zhan G; Fan S; Dickerson JE; Landry TA; Bergamini MV; Camras CB
    J Glaucoma; 2007 Mar; 16(2):189-95. PubMed ID: 17473728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.
    Fellman RL; Sullivan EK; Ratliff M; Silver LH; Whitson JT; Turner FD; Weiner AL; Davis AA;
    Ophthalmology; 2002 May; 109(5):998-1008. PubMed ID: 11986110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients.
    Konstas AG; Kozobolis VP; Katsimpris IE; Boboridis K; Koukoula S; Jenkins JN; Stewart WC
    Ophthalmology; 2007 Apr; 114(4):653-7. PubMed ID: 17197028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension.
    Goldberg I; Cunha-Vaz J; Jakobsen JE; Nordmann JP; Trost E; Sullivan EK;
    J Glaucoma; 2001 Oct; 10(5):414-22. PubMed ID: 11711841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma.
    Konstas AG; Mikropoulos D; Kaltsos K; Jenkins JN; Stewart WC
    Ophthalmology; 2006 Mar; 113(3):446-50. PubMed ID: 16513458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution.
    Denis P; Andrew R; Wells D; Friren B
    Eur J Ophthalmol; 2006; 16(3):407-15. PubMed ID: 16761242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension.
    Brandt JD; Cantor LB; Katz LJ; Batoosingh AL; Chou C; Bossowska I;
    J Glaucoma; 2008; 17(3):211-6. PubMed ID: 18414107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma.
    Konstas AG; Mikropoulos D; Haidich AB; Ntampos KS; Stewart WC
    Br J Ophthalmol; 2009 Apr; 93(4):481-5. PubMed ID: 19019932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
    Parrish RK; Palmberg P; Sheu WP;
    Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; Hoop J; Morgan L; Wudunn D; Catoira Y;
    Br J Ophthalmol; 2006 Nov; 90(11):1370-3. PubMed ID: 16825272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy.
    Kitazawa Y; Smith P; Sasaki N; Kotake S; Bae K; Iwamoto Y
    Eye (Lond); 2011 Sep; 25(9):1161-9. PubMed ID: 21701528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
    J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of travoprost 0.004% ophthalmic solution, six weeks after its laminated packaging had been removed, in primary open-angle glaucoma: a randomized, controlled, investigator-blinded study.
    Reis R; dos Santos LC; Vila MP; Magacho L
    Clin Ther; 2004 Dec; 26(12):2121-7. PubMed ID: 15823775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension.
    Cohen JS; Gross RL; Cheetham JK; VanDenburgh AM; Bernstein P; Whitcup SM
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S45-52. PubMed ID: 15016561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.